Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived
- 1 November 2009
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 83 (5), 449-454
- https://doi.org/10.1111/j.1600-0609.2009.01295.x
Abstract
Bortezomib has proven to be effective as single agent in myeloma patients. Aim of this study was to evaluate the efficacy and toxicity of bortezomib in combination with dexamethasone in a cohort of multiple myeloma (MM) relapsed/refractory patients treated in a single center. In this single center study, 70 patients were treated with bortezomib alone (9) or in combination with dexamethasone (61). Forty-one patients (59%) achieved at least a partial response (PR), including 7% complete response (CR), 36% very good partial response (VGPR) reaching the best response within four cycles. The duration of response was significantly longer for patients achieving CR/VGPR than for those achieving PR (7.3 vs. 3.8 months, P = 0.03). Likewise, time to progression, time to alternative treatment, and treatment free interval were significantly better for patients obtaining CR/VGPR (6.8, 9.4, 6.5 months respectively) as compared with PR (4.9, 6.3, 2 months respectively). The only dose-limiting toxicity was peripheral neuropathy (PN), which occurred in 38/70 patients (55%) and was of grade 3-4 in 12 (17%). PN led to a dose reduction or treatment discontinuation in 17 (24%) patients. Complete resolution or improvement of PN occurred in 29/38 (76%) after a median time of 100 d (range: 17-202). Bortezomib in combination with dexamethasone is highly effective in relapsed/refractory MM producing an impressive rate of CR/VGPR, but responses are short-lived.Keywords
This publication has 17 references indexed in Scilit:
- High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access programBritish Journal of Haematology, 2008
- Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialBlood, 2007
- The Treatment of Relapsed and Refractory Multiple MyelomaHematology, 2007
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- Clinical Course of Patients With Relapsed Multiple MyelomaMayo Clinic Proceedings, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003
- Treatment Approaches for Relapsing and Refractory Multiple MyelomaActa Oncologica, 2000
- Phase III Study Comparing Vincristine, Doxorubicin (Adriamycin), and Dexamethasone (VAD) Chemotherapy with VAD Plus Recombinant Interferon Alfa-2 in Refractory or Relapsed Multiple MyelomaAmerican Journal of Clinical Oncology, 1995